# Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

> **NCT06642545** · PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** RC148
- **DRUG:** Albumin-bound Paclitaxone
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06642545
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642545, "Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06642545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*